Prosecution Insights
Last updated: April 19, 2026
Application No. 18/634,083

TETRADENTATE PLATINUM AND PALLADIUM COMPLEXES BASED ON BISCARBAZOLE AND ANALOGUES

Final Rejection §112
Filed
Apr 12, 2024
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Arizona Board of Regents
OA Round
5 (Final)
81%
Grant Probability
Favorable
6-7
OA Rounds
2y 3m
To Grant
65%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
1407 granted / 1741 resolved
+20.8% vs TC avg
Minimal -16% lift
Without
With
+-16.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
54 currently pending
Career history
1795
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
15.2%
-24.8% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
42.6%
+2.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1741 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to paper filed on March 3, 2026, the applicants have amended claims 5 and 15. Claims 5 and 7-19 are pending in the application. Response to Arguments Applicant’s arguments, see paper, filed March 3, 2026, with respect to claims 5 and 7-19 have been fully considered and are persuasive. Therefore, all rejections are withdrawn since the applicants have amended claims to overcome indefiniteness and Improper Markush Group rejections. NEW GROUNDS OF REJECTION Claim Rejections - 35 USC § 112 5. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5 and 7-19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claim 5, the values of variables L1, L2 and L3 are defined. However, according to amended claim 5, variable L1 is absent and variables L2 and L3 represent single bonds only. In independent claim 5, last line, the term - - L5 and L6 are each not a single bond - - is vague and indefinite since according to the values defined for variables L5 and L6, they cannot represent a single bond. Claim 7 depends upon claim 5 and further defines variable L1 to be present and therefore, lacks antecedent basis since variable L1 is absent in amended claim 5. In claim 15, variable R9 is defined. However, this variable is not present in amended claim 15. Claim 15 depends upon claim 5 and further defines the value of variable X2 as NR, S=O, O=S=O, Se=O and O=Se=O in addition to other values. However, according to amended claim 5, X2 cannot represent NR, S=O, O=S=O, Se=O and O=Se=O and therefore, lacks antecedent basis. Claim 16 recites the limitation "N for the value of variable X2" in claim 5 (see first two complexes in 2nd row on page 13 and 3rd row on page 14). There is insufficient antecedent basis for this limitation in the claim. Claim 18 recites the limitation "light emitting diode" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Claim 19 recites the limitation "light emitting diode" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Apr 12, 2024
Application Filed
Jan 14, 2025
Non-Final Rejection — §112
Apr 16, 2025
Response Filed
Apr 23, 2025
Final Rejection — §112
Jul 25, 2025
Request for Continued Examination
Jul 28, 2025
Response after Non-Final Action
Aug 28, 2025
Final Rejection — §112
Oct 14, 2025
Interview Requested
Oct 20, 2025
Examiner Interview Summary
Oct 20, 2025
Applicant Interview (Telephonic)
Nov 13, 2025
Examiner Interview Summary
Nov 13, 2025
Applicant Interview (Telephonic)
Nov 30, 2025
Non-Final Rejection — §112
Mar 03, 2026
Response Filed
Mar 20, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594251
BENZALKONIUM CHLORIDE FORUSE IN TREATING CONJUNCTIVITIS AND/OR COVID-19
2y 5m to grant Granted Apr 07, 2026
Patent 12583829
SALT OF BENZOTHIAZOLE COMPOUND, AND CRYSTAL FORM AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12581852
COMPOUND, LUMINESCENT MATERIAL, DELAYED FLUORESCENT MATERIAL, AND ORGANIC OPTICAL DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12569479
BUPROPION AS A MODULATOR OF DRUG ACTIVITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564586
KAPPA OPIOD RECEPTOR ANTAGONISTS FOR TREATING PAIN-RELATED SLEEP DISORDERS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

6-7
Expected OA Rounds
81%
Grant Probability
65%
With Interview (-16.0%)
2y 3m
Median Time to Grant
High
PTA Risk
Based on 1741 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month